If process is product, mustn’t quality be top of strategy in Indian pharma?

  In the tsunami of Bihar election news, a significant development got swept away last weekend. It was the announcement by Dr Reddy’s Laboratories that three of its manufacturing plants in India had received US FDA warning letters. Today, Mint reports that the American regulator has sought third party audit across the pharma company’s entire […]

What’s wrong in govt consulting industry for policies?

  Last week the famous whistle blower in Ranbaxy data fudging case wrote in Scroll that the Indian drug regulator is “inept” in regulating biosimilars, a new class of drugs that have come to dominate the market and will increasingly do so for the next decade.   Dinesh Thakur certainly has a point but it […]